In Vivo CAR Therapies Report
Over the last few years In Vivo CAR Therapies have been increasing in popularity as a potential treatment for various cancer indications and auto-immune diseases.
The lower manufacturing costs of this exciting new modality, in comparison to ex vivo CAR T-cell therapies, make in vivo CAR therapies an attractive prospect for drug developers.
With exclusive data from Beacon, this review contains:
- An overview of the in vivo CAR Therapy landscape and the therapies currently clinically active
- A look at the potential delivery systems and disease indications for in vivo CAR therapies
- An outline of the collaborations and financial deals in the in vivo CAR therapy space.
You May Also Be Interested In…
What is Beacon?
Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.
Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.
This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.
We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!
